华特达因(000915) - 2023 Q1 - 季度财报

Financial Performance - In Q1 2023, the company achieved operating revenue of CNY 561 million, a decrease of 7.28% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 164 million, reflecting a growth of 4.94% year-on-year[5] - The subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., reported operating revenue of CNY 550 million and net profit of CNY 315 million, with year-on-year increases of 2.98% and 10.13%, respectively[4] - Total operating revenue for Q1 2023 was CNY 561,439,253.57, a decrease of 7.26% compared to CNY 605,516,557.27 in Q1 2022[15] - Net profit for Q1 2023 was CNY 314,399,174.09, representing an increase of 6.00% from CNY 294,239,667.77 in Q1 2022[15] - The company reported a net profit attributable to shareholders of CNY 163,725,554.07 for Q1 2023, compared to CNY 156,021,080.23 in Q1 2022, reflecting an increase of approximately 4.3%[16] - Total comprehensive income for Q1 2023 was CNY 314,399,174.09, compared to CNY 294,239,667.77 in Q1 2022, indicating an increase of approximately 6.8%[16] Cash Flow and Liquidity - The net cash flow from operating activities increased by 21.41% to CNY 335 million compared to the previous year[5] - Net cash flow from operating activities for Q1 2023 was CNY 335,465,224.39, up from CNY 276,299,060.18 in the same period last year, indicating a growth of about 21.4%[16] - The company experienced a net cash outflow from investing activities of CNY -106,073,536.81 in Q1 2023, compared to a net inflow of CNY 46,462,512.22 in Q1 2022[16] - Cash flow from financing activities showed a net outflow of CNY -235,465,952.17 in Q1 2023, contrasting with a net inflow of CNY 3,842,061.89 in Q1 2022[17] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 1,732,064,421.56, a decrease from CNY 1,528,339,147.89 at the end of Q1 2022[17] Assets and Liabilities - Total assets at the end of Q1 2023 reached CNY 4.82 billion, up 2.73% from the end of the previous year[5] - The company's total assets increased to CNY 4,818,661,151.84, up from CNY 4,690,492,822.90 at the end of Q1 2022[14] - Total liabilities rose to CNY 947,209,068.42, compared to CNY 629,027,439.57 in the same period last year[14] - The equity attributable to shareholders increased by 6.34% to CNY 2.75 billion compared to the end of the previous year[5] - The equity attributable to shareholders of the parent company increased to CNY 2,747,813,822.68, up from CNY 2,584,088,268.61 year-over-year[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,304[11] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[11] - The company reported a total of 10 major shareholders with varying percentages of ownership, the largest being 22.00%[11] Other Financial Metrics - The company reported a significant increase in accounts receivable by 65.17% to CNY 89.52 million, primarily due to the increase in receivables from the subsidiary[8] - Other receivables surged by 100.93% to CNY 19.04 million, attributed to increased government subsidy receivables[8] - The company experienced a 603.93% increase in other income, totaling CNY 14.91 million, mainly due to higher government subsidies[8] - The company’s basic earnings per share rose by 4.48% to CNY 0.70 per share[5] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.70, up from CNY 0.67 in Q1 2022, marking a growth of about 4.5%[16] Research and Development - Research and development expenses for Q1 2023 were CNY 11,073,221.93, a decrease from CNY 12,769,669.95 in Q1 2022[15] Future Outlook - Future outlook includes continued focus on market expansion and new product development to drive growth[15]